<DOC>
	<DOC>NCT01679327</DOC>
	<brief_summary>This study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the treatment, the investigators detect the VEGF-A,VEGF-C,VEGF-D,VEGFR-1,VEGFR-2,VEGFR-3 expression in tumor tissue by IHC and detect those protein expression level in plasma by ELISA. After at least 6 weeks treatment, the investigators detect again VEGF-A,VEGF-C,VEGF-D expression level in plasma by ELISA. The aim of the study is to identify whether those biomarkers could predict Bevacizumab efficacy.</brief_summary>
	<brief_title>Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>More than 18years old,male or female Pathologically approved as unresectable/metastatic colorectal cancer KPS &gt; 70% or ECOG 02 HGB &gt; 80 g/L, NEUT ≥ 1.5x109 /L, PLT ≥ 80x109 /L; CR &lt; 1.5 x Upper normality， TB &lt; 1.5 X Upper normality，AST or ALT &lt; 2.5 x Upper normality. Signed consent Other malignancies simultaneously except in situ cervix or nonmelanoma skin cancer Pregnancy or in lactation HGB &lt; 80 g/L, NEUT &lt; 1.5x109 /L, PLT &lt; 80x109 /L; CR ≥ 1.5 x Upper normality， TB ≥ 2.5 X Upper normality，AST or ALT ≥2.5 x Upper normality，AKP ≥ 2.5 X Upper normality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>